Aurinia Pharmaceuticals Inc

86

of 100 · stored research reading

Stored Quality research reads 86 of 100, in the strongest band of the covered universe. The underlying fundamental measurements behind this reading are consistent rather than mixed.

Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.

57

of 100 · stored research reading

Stored Fundamental Momentum research reads 57 of 100. Stored measurements classify recent reported fundamentals as middle. This describes reported financial change already disclosed, with no forward-looking claim.

Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.

50

of 100 · stored research reading

Stored Capital Returns research reads 50 of 100, recorded as moderate. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has increased at about 0.3% a year in the stored window.

Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.

Valuation context

Price / earnings

7.4

Stored ratios recorded at the last research date (2026-10-28). Valuation Intelligence remains research context and is not a validated allocation signal.